Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair.
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and ...
Zacks Investment Research on MSN
BEAM eyes global expansion of AATD study after strong early data
Beam Therapeutics BEAM announced positive updated safety and efficacy data from a phase I/II study evaluating its pipeline ...
1d
Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026
Beam Therapeutics (NASDAQ:BEAM) executives and clinical collaborators presented updated top-line data from the company’s ...
Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins ...
Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results